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Summary and Implications 
 Multi-drug resistant (MDR) strains of Salmonella 
enterica serovar Typhimurium are of increasing concern in 
the food industry and on the farm.  While these strains are 
becoming increasingly resistant to commonly used 
antimicrobial agents, they remain sensitive to killing by 
their natural predators, bacteriophage.  Bacteriophage are 
able kill MDR strains of Salmonella in vitro.   We have 
recently tested the ability of a well-known salmonella 
bacteriophage, Felix 01 and two recently isolated phage 
(HL03 and HL18) to reduce the Salmonella Typhimurium 
burden in orally challenged, susceptible mice.  When each 
of the phage was given at the same time as the oral 
Salmonella challenge, they significantly reduced the 
Salmonella burden in the treated mice.  This lowering of 
Salmonella load occurred when the phage were given at a 
1:10, 1:50 and 1:100 MOI when compared to the bacterial 
challenge dose.  Interestingly, of the three phage tested 
(Felix, HL03 and HL18), only the last phage, HL18 was 
effective when given an hour before or an hour after 
Salmonella challenge.  Felix01 and HL03 were both 
ineffective when given an hour before or an hour after 
challenge, but consistently lowered the bacterial burden in 
these mice when given at the same time as the challenge 
dose. These data indicate that bacteriophage-based therapy 
may be an alternative to antibiotic-based treatments to lower 
the Salmonella levels in swine and potentially limit the 
spread of Salmonella during transport and lairage of swine 
prior to slaughter..  
Introduction 
 Foodborne salmonellae causes an estimated 1.4 million 
cases of salmonellosis each year in the United States alone.  
Recent studies have indicated that a significant number or 
retail ground meat sources, such as ground chicken, turkey, 
pork and beef contain various serovars of Salmonella 
enterica.  When these bacteria isolated from retail meat 
sources were further tested, researchers found that 84% of 
them were resistant to at least one antibiotic and 53% were 
resistant to three or more antibiotics, including those 
antibiotics commonly used to treat salmonellosis.  If 
infected with multi-drug resistant (MDR) Salmonella, 
people are significantly more likely to be hospitalized and to 
stay in the hospital longer than those people infected with 
antibiotic-susceptible Salmonella.  
 One promising method to control MDR strains of 
bacteria is the use of lytic bacteriophage to kill bacterial 
cells.  This method has been shown to be effective against 
group A streptococcal infection, Vibrio vulnificus and 
Enterococcus faecium in mice and against E. coli infection 
in chickens.  We have recently isolated two environmental 
bacteriophage that are able to lyse multidrug resistant 
Salmonella in vitro.  In this study we tested these two phage 
with a well characterized lytic bacteriophage, Felix01 to 
determine the phage’s ability to decrease the burden of 
MDR Salmonella Typhimurium in susceptible mice.  
 
Materials and Methods 
Each phage (HL3, HL18, and FO) was cultured 
overnight with Salmonella in GCA medium.  The culture 
was centrifuged for 30 minutes at 4C to remove bacterial 
debris and the supernatant phage lysate was harvested.   
Phage lysate was filtered through a 0.22um disposable filter 
and stocks were kept at 4C.  The concentration of phage 
particles was determined by plaque assay and expressed as 
plaque forming units (PFU) per milliliter. 
For the mouse model of salmonellosis we used an oral 
challenge model.  Briefly, male C57BL6 mice were 
inoculated via gastric feeding needle with approximately 107 
CFU/mouse of Salmonella X4232  NalR GFP in 0.1 mL of 
PBS.  The mice were then treated with either PBS (negative 
control), live phage (either HL03, HL18 or Felix 01) or 
autoclaved phage (killed phage control). Bacteriophage 
(Felix01, HL18 or HL03) were given at a concentration of 
108 PFU/mouse at the same time the mice were inoculated 
with 107 CFU/mouse Salmonella Typhimurium (X4232).  In 
dose titration experiments, the mice were given 107 
CFU/mouse Salmonella Typhimurium, and varying doses of 
each of the three bacteriophage.  Four hours after 
inoculation with Salmonella, the mice were killed by CO2 
administration and the cecum and intestine were harvested 
from each.  Tissues were homogenized, homogenates were 
diluted out and plated onto XLD plates containing naldixic 
acid and onto blood agar plates (to assure no Nal-susceptible 
contaminants existed).  Data are expressed as CFU/gram of 
tissue. . 
Results and Discussion 
As shown in Figures 1 and 2, Felix 01 administration 
significantly reduced the levels of Salmonella Typhimurium 
in inoculated mice.  When given at an MOI of 10:1 or 100:1 
PFU:CFU ratio, Felix was able to reduce bacterial the 
burden of Salmonella in the intestines and ceca of infected 
mice.  This reduction was not seen at a 10:1 MOI if the 
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phage treatment was given one hour before or one hour after 
Salmonella challenge.   
 
 
Figure 1. Dose response of Felix01 against murine salmonellosis. 
1
2
3
4
5
6
7
Cecum Intestine
Lo
g 
C
FU
/g
ra
m
 ti
ss
ue
PBS
1:100 Felix 01
1:10 Felix 01
1:100 Heat-Killed Felix 01
**
**
**
**
 
 
Figure 2 Timing of Felix01 administration determines its efficacy in vivo. 
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We saw similar, but distinctive results with similar 
experiments testing the lab isolate, HL18.  As shown in 
Figure 3, the HL18 bacteriophage significantly reduced the 
levels of Salmonella in the tissues tested at an MOI as low 
as 1:1.  Also of note, a 1:10 dose of HL18 was able to 
significantly lower the Salmonella load in the intestines and 
ceca of mice treated before, after or at the same time as the 
inoculation (Figure 4).   
Figure 3.  Dose response of HL18 treatment of oral salmonellosis in mice.
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Figure 4. Effect of timing on the efficacy of HL18 administration.
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The same challenge experiments using HL03 to treat 
the mice showed that HL03 was less effective against 
Salmonella Typhimurium in vivo.  The dose-response curve 
(Figure 5) showed r an MOI of 1:50 was required to 
significantly reduce the Salmonella levels in the ceca of 
infected mice.  
Figure 5. Dose response of HL03 treatment of oral salmonellosis in mice.
2
3
4
5
6
7
8
Cecum Intestine
L
og
 C
FU
 p
er
 G
ra
m
 T
iss
ue
PBS
1:1 HL03
1:10 HL03
1:50 HL03
1:50 Killed HL03
*
*
*
*
*
 
These data indicated that while both Felix01 and HL18 
could lower Salmonella counts in the alimentary canal of the 
mice, HL03 required higher doses for similar effects and did 
not consistently reduce Salmonella levels in mice, even 
when given in 10-fold excess of the challenge dose.  Upon 
comparing HL18 and Felix01 it was discovered that the 
environmentally isolated HL18 bacteriophage was effective 
at lower concentrations and had a longer time range in 
which it could be administered to still see an effect.  
Preliminary in vitro work on other MDR Salmonella 
serovars shows that HL18 is effective against them as well. 
Taken together, these data provide evidence for an effective 
strategy to limit the growth of Salmonella, even those 
Salmonella strains resistant to multiple commonly used 
antimicrobial agents.   
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